CERT logo

CERTARA INC

CERTNASDAQ
πŸ† #2042 by market capEarnings Nov 5 Β· PostUS Equity
$11.10β–Ό $0.40 (βˆ’3.44%)
Latest quote
πŸ””
Track CERT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.4%
7dβ–² 9.9%
14dβ–² 14.9%
30dβ–² 19.8%
ytdβ–² 26.0%
1yβ–Ό 4.0%
🏦Market Cap
$1.69B
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.7%
Slowing
πŸ“ŠGross Margin
61.9%
High
πŸ’΅FCF Margin
13.4%
Healthy
βš–οΈP/S Ratio
4.1x
Fair
Otter Score
84
Strong

Trading Snapshot

Day Range
$11.08 – $11.57
52-Week Range
$4.45 – $12.94
Volume (shares)
91,924
Avg Volume (shares)
β€”
Shares Outstanding
152.5M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
$419M
Last Q Revenue
$93M
P/E Ratio
β€”
P/S Ratio
4.1x
EPS (TTM)
$-0.44
Dividend Yield
β€”
Dilution (1yr)
βˆ’0.5%
CERT logo

CERTARA INC

CERT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$419Mβ–² +8.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.5%β–² +2.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$21Mβ–Ό βˆ’1314.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$70Mβ–² +17.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
160.4Mβ–Ό βˆ’0.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$178Mβ–² +$311M YoY
StockOtter Β· stockotter.space

About CERTARA INC

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100
Analyst data unavailable.

Latest News & Updates

News unavailable.